Budget impact analysis of EGFR mutation liquid biopsy for first- And second-line treatment of metastatic non-small cell lung cancer in Greece

Mindy Cheng, Athanasios Akalestos, Sidney Scudder

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Within the European Union, Greece has the highest incidence of lung cancer among people under 45 years of age. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are indicated for the treatment of patients with EGFR mutation-positive metastatic non-small cell lung cancer (mNSCLC). Tumor tissue biopsy is the standard method for EGFR mutation detection but is invasive, is resource-intensive, and has risks of complications. The objective of this analysis was to estimate the financial impact on the Greek National Health System of adopting plasma biopsy and to identify the cost-optimal approach for EGFR mutation testing of patients with mNSCLC. We developed a budget impact model to estimate total costs for three EGFR mutation testing approaches: (1) plasma test, (2) combined testing (tissue and plasma test), and (3) reflex testing, compared to the current scenario of tissue biopsy only. One-way sensitivity and scenario analyses were conducted to evaluate the impact of uncertainty and variance of different input parameters on the results. In the first-line (1L) setting, base-case results showed that adopting plasma testing in a combined testing approach identified more EGFR mutation-positive patients and yielded cost savings (-€17 per correctly classified patient) relative to tissue testing alone. The reflex testing approach was the cost-optimal strategy in the second-line (2L) setting as it identified the most EGFR mutation-positive patients with cost savings of -€42 per correctly classified patient relative to tissue testing alone. This analysis suggests that access to both EGFR mutation tissue and plasma testing are important for optimizing mNSCLC treatment decisions in Greece. Inclusion of plasma testing in either a combined or reflex testing approach may be cost optimal for EGFR mutation plasma test implementation.

Original languageEnglish (US)
Article number429
Issue number6
StatePublished - Jun 2020
Externally publishedYes


  • Budget impact
  • Companion diagnostic
  • Cost
  • Epidermal growth factor receptor (EGFR)
  • Non-small cell lung cancer (NSCLC)
  • Plasma biopsy

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'Budget impact analysis of EGFR mutation liquid biopsy for first- And second-line treatment of metastatic non-small cell lung cancer in Greece'. Together they form a unique fingerprint.

Cite this